The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience.
 
Evangelia Vlachou
No Relationships to Disclose
 
Noah M. Hahn
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; ImmunityBio; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst)
 
Alix Dabb
Stock and Other Ownership Interests - Abbvie (I)
 
Burles Avner Johnson
Consulting or Advisory Role - Seagen
 
M. Susan Lefande
No Relationships to Disclose
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Roche/Genentech; Seagen
Research Funding - Foundation Medicine; Genentech; Genentech; Sanofi
Travel, Accommodations, Expenses - Roche/Genentech